Amgen AI Strategy: Putting AI and Data at the Heart of R&D
How Amgen uses AI on its own work: convergent innovation, a new R&D, AI and data leader, ChatGPT Enterprise across the company and AI in drug discovery. Updated November 2026.
Biotechnology medicines for cardiovascular disease, oncology, inflammation and rare diseases
Amgen has no standalone AI strategy document. Its approach comes from its April 2026 leadership release on convergent innovation and company stories.
Read the company sourceWhere Amgen Is Going with AI
Amgen is reorganizing so that AI and data sit inside research and development. From June 2026, James Bradner leads research and development, AI and data in one executive role, and Sean Bruich became Chief Technology Officer (Amgen, April 2026). Amgen has no standalone AI strategy document, so this profile draws on company releases and stories.
Amgen calls its approach convergent innovation. The company describes it as bringing together biology, data science and advanced technologies such as AI to speed up discovery and development. David Reese, then Chief Technology Officer, said in 2024: “We’re living through a ‘hinge moment,’ merging tech and biotech to revolutionize drug discovery.”
The focus has four parts.
- Drug discovery: generative biology models that design protein-based molecules, with scientists running millions of simulations at a time
- Human data: a supercomputer at its deCODE genetics unit in Iceland that analyzes a 200-petabyte library of deidentified human data
- Everyday work: ChatGPT Enterprise across the company, after an earlier rollout of Microsoft Copilot
- Software development: OpenAI’s Codex for routine coding work, according to an OpenAI customer video in June 2026
What It Takes: New Leaders, Company-Wide Tools and Human Data
Amgen uses ChatGPT Enterprise across the company, after giving Microsoft Copilot to 20,000 staff in May 2024. By mid-2025, employees were using ChatGPT more, and Amgen widened its use (Bloomberg, June 2025).
Employees helped choose the tool. Sean Bruich, then Senior Vice President of AI and Data, told Bloomberg: “OpenAI has done a tremendous job making their product fun to use.” Amgen said in August 2025 that it scaled ChatGPT Enterprise in phases so it could test the value.

AI leadership now sits in research and technology. Bradner’s role joins research with AI and data, and Bruich, who built Amgen’s AI and data capabilities, now runs technology. Chairman and CEO Robert A. Bradway credited Reese with building capabilities for “what we call convergent innovation.”
Governance rests on a published AI vision. Amgen has published an Artificial Intelligence Vision that commits it to building trustworthy AI tools and using them responsibly, and it rolled out ChatGPT Enterprise in phases with security checks.
Headcount is growing. Amgen had about 31,500 employees at the end of 2025, up 12% in a year. The sources reviewed do not link Amgen’s headcount to AI.
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Not published. ChatGPT Enterprise is available across the company, but Amgen has set no required level for all staff.
- Highest level evidenced: Level 3 (Integrating), company-claimed. Scientists use generative biology models to design molecules and run millions of simulations as part of discovery. Amgen has published no results for this work.
- Portfolio design: Amgen pairs company-wide AI tools for everyday work with AI built into drug discovery, backed by its own human data.
How Amgen Measures Results
Amgen reports no AI results for its own work. It has published no adoption rates, time savings or cost figures for ChatGPT Enterprise, Codex or its discovery models.
The evaluations it shares are qualitative. Bruich said internal testing showed GPT-5 had “notable improvements in objective measures like accuracy and reliability.” Measuring discovery cycle times and hours saved would be the step from AI adoption to AI value.
Next markers: results from convergent innovation in research and development, adoption figures for ChatGPT Enterprise, the first priorities of Bradner and Bruich, and headcount for 2026.
Change log
- May 2024: Amgen gives Microsoft Copilot to 20,000 staff.
- June 2025: Bloomberg reports that Amgen employees have shifted to ChatGPT.
- August 2025: Amgen says it has scaled ChatGPT Enterprise and tested GPT-5.
- April 2026: Amgen combines research and development with AI and data under Bradner and names Bruich Chief Technology Officer, effective June 2026.
The Bottom Line
- Disclosure: 3 of 4. Amgen answers where it is going, where it will focus and what it will take, but it reports no AI results.
- Convergent innovation joins biology, data and AI under one research leader.
- Employees helped steer the tool choice, and ChatGPT Enterprise is now used across the company.
- Level 3 is evidenced in drug discovery, on company-claimed descriptions.
- The say-do gap is measurement. Amgen calls this a hinge moment but publishes no numbers.
- Watch the new leaders. The test is whether Bradner and Bruich report results from AI in research and development.
Revenue, Headcount and Revenue per Employee
What the numbers show: Revenue rose 40% from 2022 to 2025 while headcount rose 25%, so revenue per employee rose 12%, to about $1.17 million. Much of the growth followed the acquisition of Horizon Therapeutics in October 2023. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2022 to FY2025
- FY2022: $26.32bn revenue, 25,200 employees, $1.04M per employee
- FY2023: $28.19bn revenue, 26,700 employees, $1.06M per employee
- FY2024: $33.42bn revenue, 28,000 employees, $1.19M per employee
- FY2025: $36.75bn revenue, 31,500 employees, $1.17M per employee
Change, FY2022 to FY2025: revenue up 40%, headcount up 25%, revenue per employee up 12%.
Notes: Revenue is total revenues, as reported. Headcount is approximate, at December 31. Amgen acquired Horizon Therapeutics in October 2023, which added revenue and employees.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: Amgen 10-K filings.
How Amgen Compares with US Pharma Peers
We looked at how Amgen compares with other US pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AbbVie | 4 of 4 | VP of AI Strategy and Partnerships | Not published; training offered at all levels | Human expertise and ethical use; no published framework | One result (regulatory writing), no total | $1.07M |
| Amgen | 3 of 4 | EVP of research, AI and data; SVP and CTO | Not published; ChatGPT Enterprise across the company | Published AI Vision; phased rollouts | None published | $1.17M |
| Bristol Myers Squibb | 4 of 4 | EVP and Chief Digital and Technology Officer | Not published; frontier models for all staff | Enterprise governance and audit controls; humans decide | Targets set, no results | $1.48M |
| Eli Lilly | 3 of 4 | Chief AI Officer | Level 1, by expectation | Eight principles, board briefings | No: capacity and deals | $1.30M |
| Gilead Sciences | 2 of 4 | Global CIO; no AI leader named | Not published; AI coach in pilot | Six published AI principles | None published | $1.73M |
| Johnson & Johnson | 4 of 4 | EVP and CIO; each function governs its own AI | Level 1, training required before access (2024) | Function-led governance; central AI board removed | Results by use case, no total | $682k |
| Merck | 4 of 4 | CEO sponsors five AI programs; CIO leads technology | Not published; 80%+ use the AI platform | Human review of AI drafts; no published framework | Results by use case, no total | $867k |
| Pfizer | 3 of 4 | Chief AI, Data and Analytics Officer | Level 1, 98% trained | Three principles, a board risk topic | Inside wider cost programs | $834k |
| Moderna AI Pacesetter | 2 of 4 | Chief People and Digital Technology Officer | Level 1, by expectation | Mentioned, not described | No: adoption figures | $414k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. Rows marked AI Pacesetter or Notable are companies outside the S&P 100 and STOXX Europe 50. They are shown for contrast and are not counted in any index figure. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is Amgen’s AI strategy for its own work?
Amgen calls its approach convergent innovation, which brings biology, data science and AI together to speed discovery and development. It is reorganizing so that AI and data sit inside research and development.
Who leads AI at Amgen?
James Bradner, Executive Vice President of Research and Development, Artificial Intelligence and Data, leads AI in research. Sean Bruich is Senior Vice President and Chief Technology Officer, and both roles took effect in June 2026 under Chairman and CEO Robert A. Bradway.
Which AI tools do Amgen employees use?
Amgen employees use ChatGPT Enterprise across the company, after an earlier rollout of Microsoft Copilot to 20,000 staff. Engineers use OpenAI’s Codex for routine coding work.
Is Amgen cutting jobs because of AI?
The sources reviewed show no AI-linked job cuts at Amgen. Headcount rose to about 31,500 at the end of 2025.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles